LEADER 04978nam 2201297z- 450 001 9910557359303321 005 20220111 035 $a(CKB)5400000000042299 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/77046 035 $a(oapen)doab77046 035 $a(EXLCZ)995400000000042299 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aMalignant Mesothelioma 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (328 p.) 311 08$a3-0365-2368-5 311 08$a3-0365-2367-7 330 $aMalignant mesothelioma (MM) is a rare and aggressive cancer, related to chronic inflammation and oxidative stress caused mainly by exposure to asbestos. Although this mineral has been banned for decades in many countries, epidemiologists predict the MM epidemic will last past 2040, raising many concerns in public health given its late diagnosis, dismal prognosis, and lack of current efficient therapies.To deal with this situation, important breakthroughs have recently been made in the understanding of MM's complex biology and the carcinogenic process of the different patterns of the disease. Examples of these include the development of new biomarkers and the deciphering of gene-environment interactions, molecular mechanisms of invasiveness, deregulated pathways, altered expression of miRNAs, DNA damage repair, or metabolic profile. From now on, MM's aggressive and chemoresistant character appears linked to a polyclonal malignancy, and heterogeneity in molecular alterations.Given these improvements, new therapeutic targets are being explored to solve the double challenge faced by clinicians. The first is to reduce tumor development and its wasting consequences as soon as possible, without resistance and with limited toxicity. The second is to stimulate the recognition of tumor cells by the induction of a specific immune response. This Special Issue will highlight all these aspects. 606 $aMedicine$2bicssc 610 $aasbestos 610 $aasbestos exposure 610 $aBAP1 610 $abiomarkers 610 $acancer biomarkers 610 $acancer-specific mutations 610 $acancers 610 $acarbon nanotubes 610 $acarcinogenesis 610 $aCDKN2A 610 $acirculating tumor DNA 610 $adendritic cells 610 $aDNA damage response 610 $aDNA methylation 610 $aDNA sequencing 610 $adrug repurposing 610 $aepigenome-wide analysis 610 $aepithelioid 610 $aextrapleural pneumonectomy 610 $afatty acid-binding protein 610 $aFDG 610 $afirst line 610 $agene expression 610 $agenomics 610 $aHippo pathway 610 $ahistotype 610 $aimmune therapy 610 $aimmunogenicity 610 $aimmunohistochemistry 610 $aimmunotherapy 610 $ainfiltrating immune cells 610 $ainflammation 610 $ainteraction analysis 610 $alaminin subunit beta-2 610 $aliquid biopsies 610 $alurbinectedin 610 $alymphocyte-to-monocyte ratio 610 $amacrophage-capping protein 610 $amalignant mesothelioma 610 $amalignant pleural mesothelioma 610 $amesothelioma 610 $amesothelium 610 $ameta-analysis 610 $ametabolomics 610 $aMPM 610 $aMTAP 610 $amutation 610 $an/a 610 $anetwork analysis 610 $aNF2 610 $aoxidative stress 610 $aPET-CT 610 $aplasma 610 $apleural effusion 610 $apleural mesothelioma 610 $apleurectomy decortication 610 $apredictive biomarker 610 $aprognostic biomarker 610 $aprotein-protein interactions 610 $aproteomics 610 $aPTCH1 610 $aradiotherapy 610 $aredox-sensitive factors 610 $asarcomatoid 610 $aselenium-binding protein 1 610 $aSETD2 610 $asurvival 610 $asurvival analysis 610 $asystematic review 610 $asystems biology 610 $atargeted therapy 610 $atherapy response 610 $atumor microenvironment 610 $atumor suppressor 610 $atumor-associated macrophages 610 $aVATS 610 $aWDPM 610 $awell-differentiated papillary mesothelioma 615 7$aMedicine 700 $aL. Pouliquen$b Daniel$4edt$01311333 702 $aKopecka$b Joanna$4edt 702 $aL. Pouliquen$b Daniel$4oth 702 $aKopecka$b Joanna$4oth 906 $aBOOK 912 $a9910557359303321 996 $aMalignant Mesothelioma$93030257 997 $aUNINA